At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 7 enrolled
Drug / intervention
PF-06372865 +2 moredrug
Likely dose
Lorazepam 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double Blind, Randomized, Cross- Over Study Examining Efficacy Of Pf-06372865 In A Photosensitivity Epilepsy Study Using Lorazepam As A Positive Control
In Brief
A Phase 2 clinical trial evaluating PF-06372865, Placebo, and 1 other intervention for Reflex Epilepsy, Photosensitive. Completed, enrolled 7 participants across 16 sites.
Detailed Summary
PF-06372865 in subjects with photosensitive epilepsy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsReflex Epilepsy, Photosensitive
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 2015
Enrollment StartDec 2015
Primary CompletionJan 2017
Study CompletionFeb 2017
TodayJul 2026
First PostedSep 30, 2015
Enrollment StartDec 16, 2015
Primary CompletionJan 10, 2017
Study CompletionFeb 7, 2017
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 10.8 years ago
Interventions
PF-06372865drug
Single dose
Placebodrug
Placebo for PF-06372865 and placebo for lorazepam
Lorazepamdrug
2 mg single oral dose